Tocilizumab for acute chest syndrome in sickle cell
Treatments studied
Part of Blood & lymphatic, Genetic & congenital, Lungs & breathing clinical trials.
This trial studies tocilizumab (a medicine that calms inflammation) to treat acute chest syndrome in people with sickle cell disease. It may help improve symptoms and recovery by targeting key immune signals involved in this complication.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 12 or older
- You have a confirmed diagnosis of sickle cell disease (Hb SS, Hb SC, Hb Sβ+, or Hb Sβ0)
- You are not pregnant and not breastfeeding
- You have not had gene therapy or a stem cell transplant in the past
- Your current blood counts are not too low (neutrophils ≥ 1000/mm³ and platelets ≥ 50,000/mm³)
- You have not had certain TB test results or active TB
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if the drug tocilizumab can help treat acute chest syndrome, a serious lung complication of sickle cell disease. It is for people with sickle cell disease who are hospitalized and need oxygen or breathing support. The study compares tocilizumab to a placebo to see if it speeds up recovery.
This trial tests CS-206, an experimental therapy for people with sickle cell disease. It aims to reduce severe complications like pain crises, acute chest syndrome, strokes, and other serious events. You may qualify if you have a specific genetic type of sickle cell disease and have experienced complications despite standard treatments.
This early trial tests crizanlizumab (a medicine for sickle cell) to see if it improves how your body matches oxygen supply with oxygen needs. It may be helpful for reducing sickle-cell–related complications by changing blood vessel and oxygen behavior.
This trial tests a new treatment called CS-206 for adolescents with severe sickle cell disease. It aims to see if this treatment can help by making stem cell transplants safer and more effective for people who have not done well with standard care.
This trial tests whether crizanlizumab can reduce painful sickle cell crises (called vaso-occlusive crises or VOCs) in people with sickle cell disease who have frequent crises. It may be an option for those who still have crises despite current treatments.
This trial tests if an intravenous medication called L-citrulline can help treat pain crises in children and young adults with sickle cell disease. Participants receive either the study drug or a placebo while in the hospital for a severe pain episode.
Hear when a new Sickle Cell Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.